Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Adicionar filtros








Tipo de estudo
Intervalo de ano
1.
Chinese Journal of Clinical Oncology ; (24): 1563-1566, 2013.
Artigo em Chinês | WPRIM | ID: wpr-439781

RESUMO

Objective:The clinical features, risk factors, and outcomes of coma were analyzed in patients treated with bevacizum-ab combined with chemotherapy This study also aims to increase the awareness on the toxicity of this regimen. Methods:Two cases of coma induced by bevacizumab combined with chemotherapy were reported. Diagnosis, treatment, and relevant literature were reviewed and discussed. Results:Inadequate blood pressure (BP) control was one of the risk factors leading to coma in patients treated with this therapy. The clinical feature of these patients was reversible posterior leukoencephalopathy syndrome (RLPS). Imaging results showed no typical finding. Reinforced supportive treatment including intensive BP control showed satisfactory outcomes. Conclusion:Coma is common in patients treated with bevacizumab combined with chemotherapy. This regimen should be used cautiously in patients with a history of hypertension. BP should be monitored closely and managed promptly during the combination therapy to prevent coma. RLPS-related coma is reversible after appropriate treatment.

2.
Chinese Journal of Primary Medicine and Pharmacy ; (12): 1751-1752, 2010.
Artigo em Chinês | WPRIM | ID: wpr-388173

RESUMO

Objective To evaluate the effect of hepatic arterial chemo-embolization( TACE) combined threedimensional conformal radiation therapy (3 D-CRT) in treatment of un- resectable primary hepatocellular cancer (PHC). Methods 80 patients with PHC were divided into TACE therapy(control group) 40 cases and 3D-CRT + TACE treatment( observation group)40 cases,The efficacy and survival rate was observed. Results The rate of effect in observation group were 35 cases (87. 5% ) higher than that 28 cases (70. 0% ) in control group ( x2 = 3. 89, P < 0.05 ) ,The rate of survival in observation group of 1、2、3-year were 67. 5% ,55. 5% ,40. 0% which were higher than that 50. 0% ,27. 5% ,15. 0% in control group( x2 = 3.4576, x2= 3.726, x2 = 3. 635, all P < 0.05), The incidence of adverse reactions in two groups had no significant difference ( P <0.05). Conclusion The three-dimensional conformal radiotherapy combined with transcatheter arterial chemoem-bolization for unresectable primary hepatocellular cancer had a better efficacy,and adverse reactions could be tolerated.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA